Sonoma Pharmaceuticals, Inc.
SNOA · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $2,718 | $2,782 | $6,628 | $21,277 |
| - Cash | $5,374 | $3,128 | $3,820 | $7,396 |
| + Debt | $305 | $608 | $849 | $1,367 |
| Enterprise Value | -$2,351 | $262 | $3,657 | $15,248 |
| Revenue | $14,288 | $12,735 | $13,272 | $12,628 |
| % Growth | 12.2% | -4% | 5.1% | – |
| Gross Profit | $5,465 | $4,745 | $4,477 | $3,993 |
| % Margin | 38.2% | 37.3% | 33.7% | 31.6% |
| EBITDA | -$3,572 | -$4,525 | -$4,445 | -$5,701 |
| % Margin | -25% | -35.5% | -33.5% | -45.1% |
| Net Income | -$3,457 | -$4,835 | -$5,151 | -$5,086 |
| % Margin | -24.2% | -38% | -38.8% | -40.3% |
| EPS Diluted | -2.79 | -5.32 | -15.18 | -19.17 |
| % Growth | 47.6% | 65% | 20.8% | – |
| Operating Cash Flow | -$88 | -$2,398 | -$6,152 | -$4,248 |
| Capital Expenditures | -$80 | -$17 | -$269 | -$137 |
| Free Cash Flow | -$168 | -$2,415 | -$6,421 | -$4,385 |